Bio Roundup: Trump’s Rx Silence, PCSK9 News, Amgen’s Migraines & More
Xconomy
NOVEMBER 18, 2016
For one new kind of cholesterol drug, insurers and their agents have tried the “just say no” strategy: refusing to pay what they deem high prices until the drug makers produce broad (and expensive) evidence that the drugs save lives. Read more » Reprints | Share: UNDERWRITERS AND PARTNERS.
Let's personalize your content